Promore Pharma reached the targeted number of patients completing treatment in the HEAL LL-37 Phase IIb clinical trial
STOCKHOLM, 24 March 2020 -- Promore Pharma AB, a Swedish biopharmaceutical developer of therapeutic peptides, today announce that last patient has been dosed in the treatment phase of the company’s Phase IIb-study (HEAL) with LL-37, a new candidate drug for treatment of venous leg ulcers. The company reached its target of treating 120 patients with LL-37 for three months. The company assesses that results from the study can be presented in the fourth quarter 2020 in accordance with earlier communications.The aim with Promore Pharma’s phase IIb study with LL-37, HEAL (A Study in Patients